RECRUITING

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Talk to us

Conditions

Age-Related Macular Degenerationscreeningartificial intelligenceAI

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Official Title

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Quick Facts

Study Start:2025-05-12
Study Completion:2026-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06924021

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
  2. * Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
  3. * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
  1. * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
  2. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center
  3. * Severe vision loss requiring urgent surgery
  4. * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
  5. * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
  6. * Unwilling to sign informed consent form
  7. * Currently or previously enrolled in an interventional AMD clinical trial

Contacts and Locations

Study Contact

Wisconsin Reading Center
CONTACT
1-608-262-1334
wrc.support@wisc.edu

Principal Investigator

Amitha Domalpally, MD, PhD
PRINCIPAL_INVESTIGATOR
UW School of Medicine and Public Health

Study Locations (Sites)

Bergstrom Eye Research LLC
Fargo, North Dakota, 58103
United States
Erie Retina Research
Erie, Pennsylvania, 16507
United States
Retina Foundation of the Southwest
Dallas, Texas, 75231
United States
University Station Eye Care Clinic
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Amitha Domalpally, MD, PhD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-12
Study Completion Date2026-11

Study Record Updates

Study Start Date2025-05-12
Study Completion Date2026-11

Terms related to this study

Keywords Provided by Researchers

  • screening
  • artificial intelligence
  • AI

Additional Relevant MeSH Terms

  • Age-Related Macular Degeneration